Halozyme Therapeutics (HALO) Reports In-Line Q1 EPS

Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $56.9 million versus the consensus estimate of $67.8 million.

GUIDANCE:

Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $209.1 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c